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ABSTRACT
Recent evidence showed that a variety of DNA damaging agents including 5-FU 
and L-OHP impairs ribosomal biogenesis activating a ribosomal stress pathway. Here, 
we demonstrate that in lung and colon cancer cell lines devoid of p53, the efficacy of 
5-FU and L-OHP chemotherapy depends on rpL3 status. Specifically, we demonstrate 
that ribosomal stress induced by 5-FU and L-OHP is associated to up-regulation of 
rpL3 and its accumulation as ribosome-free form. We show that rpL3 participates in 
the cell response to chemotherapy acting as a critical regulator of cell cycle, apoptosis 
and DNA repair, by modulating p21 expression. Moreover, we demonstrate that rpL3 is 
able to control DNA repair also independently from p21 status of cell. It is noteworthy 
that silencing of rpL3 abolishes the cytotoxic effects of 5-FU and L-OH indicating that 
the loss of rpL3 makes chemotherapy drugs ineffective. Taking together our results 
shed light on 5-FU and L-OHP mechanism of action and contribute to more effective 
clinical use of these drugs in cancer therapy.
INTRODUCTION
A major role of nucleolus is the production of 
small and large ribosome subunits; however as involved 
in additional cellular functions, provides a link between 
ribosome subunits biosynthesis, cell cycle progression 
and stress signaling [1–3]. Recently, some evidence, 
indicate that 5-fluouracil (5-FU) and Oxaliplatin (L-OHP) 
represent two chemotherapeutic molecules exerting 
inhibitory effect on ribosome biogenesis [4]. Three 
different levels for perturbation of ribosome biogenesis by 
chemotherapeutic drugs have been defined, i.e. inhibition 
of rRNA gene transcription, inhibition of early and late 
maturation of rRNA precursors, and perturbation linked 
to disintegration of nucleolar structures [5–7]. Drugs 
which inhibit the rRNA transcription and early processing 
of 32S rRNA precursor, such as L-OHP, promote the 
nucleoplasmic translocation of nucleophosmin (NPM), a 
well-known marker of nucleolar disruption [8]. However, 
nucleolar breakdown does not seem to be an essential step 
for activation of the ribosomal stress pathway. In fact, 
5-FU, which inhibits rRNA late processing steps, does not 
induce NPM translocation into the nucleoplasm.
5-FU and L-OHP are widely used for therapy of a 
variety of solid tumors. Increased understanding of the 
mechanism of action of these two drugs has led to the 
development of strategies that enhance their anticancer 
activity. Despite these advances, response rates to 
5-FU-based chemotherapy, alone or in combination 
with L-OHP, does not exceed 40–50%. In addition, 
development of drug resistance during the therapy 
remains a major problem [9].
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During the last few years, the effects of 5-FU on 
cell growth arrest and apoptosis have been attributed 
to a p53-dependent stress signaling pathway, activated 
in response to disruption of ribosomal biogenesis [10]. 
This type of p53-activating stimulus involves a subset of 
ribosomal proteins (rp), including rpL11, rpL23, rpL5, 
rpS7 [11]. These proteins affect human double minute-2 
(HDM2)-p53 circuit and lead to accumulation of p53 
causing p53-dependent cell-cycle arrest [12–14].
It is known that most cancer cells contain mutant 
p53 or no p53 at all [15, 16]. In recent years, some data 
revealed the existence of p53-independent mechanisms 
involving ribosomal proteins that link nucleolar stress to 
cell cycle arrest [17–19].
We have studied post-transcriptional regulatory 
strategies of mammalian ribosomal proteins (r-proteins), 
and we demonstrated that human rpL3 autoregulates its 
own expression through alternative splicing associate to 
nonsense-mediated mRNA decay. We have also identified 
hnRNP H1, NPM and KHSRP as transacting factors 
involved in the regulation of the alternative splicing of 
rpL3 gene and analysed their role in rpL3 autoregultory 
circuit [20].
We have recently demonstrated that human 
rpL3 exerts an extra-ribosomal function resulting in 
the induction of p21-dependent cell growth arrest and 
apoptosis in the absence of p53 [21]. In this paper, we 
demonstrate that ribosome-free rpL3 plays a critical role 
in cell response to ribosome stress induced by 5-FU and 
L-OHP treatments. Our data show that rpL3 is involved in 
drug-induced cell-cycle arrest, apoptosis and DNA repair 
by controlling p21 expression. In addition, rpL3 is also 
able to control DNA repair in a p21-independent manner. 
Finally, we report that the absence of rpL3 is dramatically 
associated to ineffectiveness of 5-FU and L-OHP.
RESULTS
5-FU and L-OHP treatments increase 
the ribosome-free form of rpL3
Ribosome biogenesis represents a target for a large 
variety of drugs for cancer therapy [3, 22]. It is known 
that upon drug-induced ribosomal stress some r-proteins 
accumulate as ribosome-free forms and induce cell growth 
arrest and apoptosis [14, 23–25]. To understand whether 
drug-induced ribosomal stress caused the accumulation 
of ribosome-free rpL3, we treated Calu-6 and HCT 116 
p53-/- cells with 100 μM of 5-FU or 10 μM of L-OHP 
corresponding to the concentrations for the complete 
inhibition of rRNA late processing steps or rRNA gene 
transcription, respectively [4]. 24 h after treatments, cells 
were collected, lysed (total fraction, TF) and fractionated 
to obtain the ribosome-associated fraction (RF) and the 
ribosome-free fraction (FF) [19]. Proteins extracted 
from each fraction were analyzed by western blotting. 
Figures 1a and 1b show that 5-FU and L-OHP treatments 
caused an increase of total rpL3 level and a significant 
accumulation of ribosome-free rpL3. 5-FU or L-OHP 
failed to increase the levels of rpL7a and rpS19, two 
arbitrary proteins of large and small subunit respectively, 
which remained largely associated to the ribosome 
(Figures 1a and 1b).
rpL3 is involved in the cell response  
to 5-FU and L-OHP
In order to understand whether the ribosome-free 
rpL3 could be involved in the cell response to 5-FU 
and L-OHP, we analyzed the influence of rpL3 on drug-
induced cell cycle modifications and apoptosis. To this 
aim, we impaired rpL3 function by incubating Calu-6 
and HCT 116 p53-/- cells with siRNA specific for rpL3. 
Then, cells were treated with 100 μM of 5-FU or 10 μM 
of L-OHP. 24 h later, rpL3 protein levels were detected by 
western blotting (Supplementary Figure 1) and cell cycle 
was analyzed by flow cytometry. The tested drugs exerted 
different effects on the cell cycle. In the presence of rpL3 
(scrambled siRNA), the addition of 100 μM of 5-FU 
caused S phase arrest, whereas incubation with 10 μM 
of L-OHP completely prevented cells to undergo DNA 
synthesis. Of interest, the depletion of rpL3 (rpL3 siRNA) 
restored normal cell cycle distribution in 5-FU or L-OHP-
treated cells. Note that in untreated cells, the silencing of 
rpL3 did not affect the cell cycle (Figures 2a and 2b).
Analogous experiments were performed by using 
low doses of ActD. To this purpose, Calu-6 cells were 
transiently transfected with rpL3 siRNA or scrambled 
siRNA. Then, cells were treated with ActD 5 nM for 24 h 
and cell cycle was analyzed by flow cytometry. As shown 
in Supplementary Figure 2 the depletion of rpL3 (rpL3 
siRNA) restored normal cell cycle distribution in ActD-
treated cells.
To study the role of ribosome-free rpL3 in the 
apoptotic response to 5-FU and L-OHP, modifications 
of mitochondrial inner membrane potential (ΔΨm) were 
estimated by tetramethylrhodamine ethyl ester (TMRE) 
staining [26]. Calu-6 and HCT 116 p53-/- cells were 
transiently transfected with rpL3 siRNA or scrambled 
siRNA. Then, cells were treated with 100 μM of 5-FU 
or 10 μM of L-OHP for 24 h TMRE-stained cells were 
analyzed by flow cytometry. As expected, the percentage 
of apoptosis increased after 5-FU or L-OHP treatments 
compared to control in each cell lines (Figures 3a and 3b). 
Interestingly, rpL3 silencing resulted in a decrease of 
apoptotic cells following 5-FU or L-OHP treatments 
(Figures 3a and 3b).
These data suggest that rpL3 was needed to mediate 
5-FU and L-OHP apoptotic cell response.
Next, we performed a clonogenic assay. To this 
aim, Calu-6 cells were transiently transfected with rpL3 
siRNA or scrambled siRNA and treated with 100 μM of 
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Figure 1: Distribution profile of rpL3 protein upon drug treatments. (a) Calu-6 cells, untreated and treated with 100 μM 5-FU 
or 10 μM L-OHP for 24 h, were collected, lysed (total fraction, TF) and fractionated to obtained the ribosome-associated fraction (RF) and 
ribosome-free fractions (FF). The fractions were analyzed by western blotting with the indicated antibodies. The per-cell ratio of the amount 
of protein loaded onto a gel was TF:RF:FF/1:10:1. Quantification of rpL3, rpL7a and rpS19 in TF (panel on the left) and quantification of 
rpL3 in FF (panel on the right) are shown. (b) Results from analogous experiments performed in HCT 116 p53-/- cells are shown. Results 
illustrated in Figures 1–8 are representative of three independently performed experiments.
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Figure 2: Effect of rpL3 silencing on cell cycle upon 5-FU and L-OHP treatments. (a) Calu-6 cells and (b) HCT 116 
p53-/- cells were transiently transfected with siRNA specific for rpL3 or scrambled siRNA (Scr) and treated with 5-FU or L-OHP for 24 h 
or untreated. Cells were stained with FITC conjugated anti-5-bromodeoxyuridine antibodies and counterstained with propidium iodide to 
analyze DNA synthesis and DNA content respectively by flow cytometry. The percentage of cells in different phases of cell cycle is shown.
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5-FU or 10 μM of L-OHP for 24 h. In cells transfected 
with scrambled siRNA, the colony number was strongly 
reduced upon exposure to 5-FU or L-OHP thus confirming 
the ability of the drugs to inhibit clonogenicity. It is 
noteworthy that following rpL3 depletion the capacity 
of cells to produce colonies upon 5-FU and L-OHP 
treatments was comparable to the capacity of untreated 
cells transfected with scrambled siRNA (Figure 3c).
rpL3 is involved in DNA damage induction
In order to analyze whether rpL3 was involved in the 
DNA damage induction we mesaured the amount of H2AX 
phosphorylation at serine 139 (termed γ-H2AX), a central 
component of various signaling pathways in response to 
DSBs [27]. To this aim, Calu-6 and HCT 116 p53-/- cells 
were transiently transfected with rpL3 siRNA, scrambled 
Figure 3: Effect of rpL3 silencing on apoptosis and cell survival upon 5-FU and L-OHP treatments. (a) Calu-6 cells and 
(b) HCT 116 p53-/- cells were transiently transfected with siRNA specific for rpL3 or scrambled siRNA (Scr) and treated with 5-FU 
or L-OHP for 24 h or untreated. Then cells were analyzed for mitochondrial membrane potential by TMRE staining. Fluorescence was 
measured by flow cytometry. (c) Clonogenic assay. Calu-6 cells transiently transfected with siRNA for rpL3 or scrambled siRNA (Scr) were 
treated with 5-FU or L-OHP for 24 h or untreated. After 10 days, colonies were stained with methylene blue, counted and photographed.
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siRNA or pHA-rpL3, a plasmid encoding rpL3-HA. 
Then, cells were treated with 100 μM of 5-FU or 10 μM 
of L-OHP for 24 h. Figure 4 showed that in untreated 
cells the depletion of rpL3 did not cause an increase 
of DNA damage. In fact, in this condition the levels of 
γ-H2AX were similar to those observed in untreated cells 
transfected with scrambled siRNA. In contrast, an increase 
of γ-H2AX amounts was detected in untreated cells after 
rpL3 over-expression. As expected, the exposure of cells 
to 5-FU and L-OHP induced an increase of γ-H2AX 
levels. The overexpression of rpL3 in these cells caused 
an additional increase of γ-H2AX indicating that rpL3 is 
able to increase DNA damage induced by 5-FU or L-OHP 
treatment. Of interest, the specific silencing of rpL3 
abolished DNA damage caused by 5-FU and L-OHP in 
each cell line (Figure 4).
rpL3 is involved in HR and NHEJ pathways
In mammals, the formation of DSBs is repaired 
mainly through two pathways, the homologous 
recombination (HR) and non homologous end joining 
(NHEJ) [28, 29]. We assessed the proficiency of cells for 
HR and NHEJ in conditions of rpL3 silencing. In order 
to study HR, HeLa/DR-GFP cells (see Materials and 
Methods) were transiently co-transfected with a plasmid 
expressing I-SceI endonuclease and rpL3 siRNA or 
scrambled siRNA (Supplementary Figure 3). 48 h post-
transfection, cells were harvested and subjected to GFP 
flow cytometry. Figure 5a shows that the depletion of rpL3 
was associated to an increase of GFP+ cells versus cells 
transfected with scrambled siRNA.
To examine the involvement of rpL3 in NHEJ, 
Calu-6 and HCT 116 p53-/- cells were used in a plasmid 
end-joining assay by using transient transfection of pGL3 
plasmid linearized with HindIII or NarI (see Materials 
and Methods). DNA repair via NHEJ was measured by 
relative luciferase activity. We observed that depletion 
of rpL3 affected luciferase production in each cell line 
(Figures 5b and 5c). Of interest, a significant increase of 
precise (error-free) DNA EJ activities in cells silenced for 
rpL3 compared to cells treated with scrambled siRNA was 
observed (Figure 5c). To better assess the role of rpL3 in 
the regulation of HR and NHEJ we evaluated the effect 
of rpL3 on DNA damage after the inhibition of DNA-PK, 
an essential component of both DNA repair pathways. To 
this aim, Calu-6 and HCT 116 p53-/- cells were transiently 
depleted of rpL3 by using specific siRNAs, and DNA-PK 
Figure 4: Effect of rpL3 on DNA damage. (a) Calu-6 cells and (b) HCT 116 p53-/- cells were transiently transfected with siRNA 
specific for rpL3 or scrambled siRNA (Scr) or pHA-rpL3 plasmid. Then, cell were treated with 100 μM 5-FU or 10 μM L-OHP for 24 h 
or untreated. The samples were immunostained with an anti-g-H2AX monoclonal antibody followed by secondary fluorescein conjugate 
antibodies and analyzed by flow cytometry.
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Figure 5: Role of rpL3 in the Homologous Recombination and Non-homologous End Joining. (a) HeLa/DR-GFP cells 
were transiently cotransfected with a plasmid expressing the I-SceI enzyme and siRNA specific for rpL3 or scrambled siRNA (Scr). 48 h 
later, cells were assayed for GFP expression by flow cytometry. Calu-6 cells and HCT 116 p53-/- cells transiently cotransfected with 
pGL3-luciferase linearized by the restriction endonuclease HindIII (b) or NarI (c) and siRNA specific for rpL3 or scrambled siRNA (Scr). 
48 h later cells were analyzed for the relative luciferase activity, normalized against Renilla Luciferase (pRL). Calu-6 cells (d) and HCT 
116 p53-/- (e) were transiently transfected with siRNA specific for rpL3 or scrambled siRNA (Scr), treated or not with 100 μM 5-FU or 
10 μM L-OHP in the presence or in the absence of the DNA-PK inhibitor NU7026. 24 h later, cells were immunostained with an anti-
γH2AX monoclonal antibody followed by secondary fluorescein-conjugate antibodies and analyzed by flow cytometry.
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was pharmacologically inhibited by using NU7026. 
Then, cells were treated with 100 μM 5-FU or 10 μM 
L-OHP and assayed for H2AX phosphorylation by flow 
cytometry. Figures 5d and 5e showed that after NU7026 
treatment, 5-FU or L-OHP treatment of rpL3-depleted 
cells was associated to a strong increase of phosphorylated 
H2AX levels. These results suggest that rpL3 is implicated 
in cell response to drugs treatment by preventing DNA 
repair via HR and NHEJ.
rpL3 regulates p21 gene transcription 
upon 5-FU or L-OHP treatments
We have previously reported that rpL3 is able to 
control p21 promoter activity [21]. Here, we investigated 
whether the reported effects of rpL3 in the cell response 
to drug treatments were related to its ability to modulate 
p21 expression. To this aim, we evaluated the effect of 
alterations in rpL3 amount on p21 promoter activity 
after drug treatments. Calu-6 and HCT 116 p53-/- cells, 
untreated or treated with 100 μM of 5-FU or 10 μM 
of L-OHP for 24 h, were collected and subjected to 
Chromatin immunoprecipitation experiments by using 
anti-rpL3 antibodies and anti-IgG as control.
The presence of rpL3 in DNA-immunoprecipitated 
complexes was assayed by western blotting. Quantitative 
PCR (qPCR) assays on the samples were performed as 
previously reported [21]. Figures 6a and 6b show that 
in untreated cells, rpL3 is able to bind p21 promoter, as 
we previously demonstrated [21]. After 5-FU or L-OHP 
treatment, the binding of rpL3 on p21 promoter was 
significantly increased compared to that observed in 
the control.
Next, to test the role of rpL3 on p21 promoter 
activity in the response to drug exposure, we performed a 
reporter luciferase assay in condition of rpL3 silencing and 
drug treatments. To this aim, Calu-6 and HCT 116 p53-/- 
cells were transiently cotransfected with the full-length p21 
promoter luciferase reporter plasmid [21] and rpL3 siRNA 
or scrambled siRNA. Then, cells were treated with 100 μM 
of 5-FU or with 10 μM of L-OHP for 24 h or untreated and 
analyzed by western blotting with anti-rpL3 and anti- p21. 
As shown in Figures 7a and 7b in untreated cells the rpL3 
silencing did not cause any alteration on p21 promoter 
activity compared to untreated cells transfected with 
scrambled siRNA (control). The treatment with 10 μM of 
L-OHP activated p21 promoter, while the exposure to 100 
μM 5-FU reduced p21 gene promoter activity.
When rpL3 expression was switched off, the effect 
on p21 gene transcription of 100 μM of 5-FU or 10 μM 
of L-OHP was completely abolished since p21 promoter 
activity was similar to that observed in the control 
(Figures 7a and 7b). These data indicated that rpL3 was 
necessary for regulating p21 promoter activity in the cell 
response to 5-FU and L-OHP.
We analyzed also the expression levels of p21 
protein in these conditions. As shown in Figures 7c and 7d, 
the treatment with 5-FU caused a reduction of p21 
amounts, whereas the addition of L-OHP enriched p21 
levels. When rpL3 was silenced, 5-FU and L-OHP failed 
to exert their effects. In fact, in these conditions p21 levels 
resulted similar to the basal levels present in the control.
rpL3 is involved in p21-dependent and  
p21-independent DNA repair
To understand whether rpL3 was involved in the 
control of DNA repair through a molecular mechanism 
mediated by p21, we used p21-depleted Calu-6 
(p21ΔCalu-6) cells in which p21 gene expression was 
stably switched off [21]. We measured DSB formation 
in p21ΔCalu-6 cells following alterations of rpL3 
expression levels. Cells were incubated with rpL3 siRNA 
or scrambled siRNA or with the plasmid pHA-rpL3. 
24 h after transfection, cells were treated with 100 μM 
of 5-FU and 10 μM of L-OHP. Untreated and treated 
cells were subjected to γ-H2AX quantification to monitor 
DSB formation by flow cytometry. Figure 8 shows that 
in untreated cells, the specific depletion of rpL3 did not 
affect DSB formation while the ectopic expression of rpL3 
induced an increase of DNA damage.
In treated cells, the silencing of rpL3 did not alter 
DSB levels indicating that p21 was required for the 
rpL3-mediated control of DNA repair. In fact, in these 
conditions the levels of γ-H2AX were similar to those 
observed in treated cells silenced with scrambled siRNA. 
Furthermore, in treated cells the overexpression of rpL3 
was still able to increase drug-induced DNA damage. 
Taken together, these results indicate that rpL3 is able to 
control DNA repair in a p21-dependent manner as well as 
through mechanisms independent from p21 status of cell.
DISCUSSION
The sensitivity variation and the development of 
resistance limit the efficiency of chemotherapy [30]. 
Several preclinical studies have demonstrated that the loss 
of p53 function reduced cellular sensitivity to 5-FU [9] 
but the molecular mechanism by which this occurs is 
still a matter of debate [31]. A better understanding of 
the molecular mechanism of anti-cancer molecules such 
as 5-FU and L-OHP, widely used for therapy of a variety 
of solid tumors [32], may contribute to improve therapy 
based on these drugs. The results reported here extend the 
scenario of mechanisms of drugs as 5-FU and L-OHP that 
specifically impact ribosome biogenesis for the treatment 
of cancers lacking active p53 and highlight the importance 
of human rpL3 as critical mediator of cell response to 
chemotherapy. Data reported here demonstrate that after 
ribosomal stress induced by 5-FU and L-OHP rpL3 is 
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Figure 6: Analysis of the interaction between rpL3 and p21 gene promoter in response to 5-FU and L-OHP treatments. 
Protein samples of DNA-rpL3 or DNA-IgG immunocomplexes from (a) Calu-6 cells and (b) HCT 116 p53-/- cells untreated or treated with 
100 μM 5-FU and 10 μM L-OHP for 24 h were analyzed by western blotting assay with antibodies against rpL3. Note the absence of signal 
in DNA-IgG immunocomplex. The same DNA-immunoprecipitates were subjected to qPCR with primers specific for the proximal region 
of p21 gene promoter or control loci (p21 3′UTR).
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Figure 7: Role of rpL3 in the regulation of p21 promoter activity upon 5-FU and L-OHP treatments. (a) Calu-6 cells and 
(b) HCT 116 p53-/- cells were transiently cotransfected with the full-length p21 promoter luciferase reporter plasmid and siRNA specific 
for rpL3 or scrambled siRNA (Scr). Then, cells were treated with 100 μM of 5-FU or with 10 μM L-OHP for 24 h and untreated. Analysis of 
the relative luciferase activity, normalized against Renilla Luciferase (pRL) activity, of the samples is shown. (c, d) Western blotting of 
protein extracts from the same samples with antibody directed against p21 protein. Loading in the gel lanes was controlled by detection 
of α-tubulin protein.
up-regulated and accumulated as ribosome-free form 
(Figures 1a and 1b).
5-FU or L-OHP treatments caused a cell cycle 
arrest and an increase of γ-H2AX levels indicative of 
a high number of DSBs [33, 34] (Figures 2a and 2b, 
Figures 4a and 4b). In these conditions the percentage of 
apoptotic cells was about 20–30% (Figures 3a and 3b) 
in p53 mutated and p53 null cell lines. The specific 
rpL3 impairment was able to completely abolish the 
cytotoxic effects of either 5-FU or L-OHP. In fact, when 
rpL3 expression was switched off we observed a strong 
reduction of DNA damage following drug incubation 
(Figures 4a and 4b) and rpL3-depleted cells not only 
survived but became able to reenter cell cycle and 
proliferate (Figure 3c). In addition, the ectopic expression 
of rpL3 either in untreated cells or treated cells induced 
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γ-H2AX formation (Figures 4a and 4b) strongly suggesting 
that rpL3 exterts itself cytotoxic effects leading to increase 
the susceptibility of tumor cells to chemotherapy.
We hypothesized that the absence of citotoxicity in 
rpL3-depleted cells exposed to 5-FU or L-OHP was due 
to an activation of DNA repair. Damage to DNA can occur 
in all cell cycle phases in proliferating cells and repair 
mechanisms involved vary in the different phases of the 
cell cycle [35, 36]. Since rpL3 seems to be involved in 
cell response to drugs that affect different phases of cell 
cycle, we supposed that rpL3 is able to influence different 
DNA repair pathways. In fact, our data indicate a strong 
correlation between intracellular levels of rpL3 and the 
activity of specific DNA repair processes such as HR and 
NHEJ implying a significant role for rpL3 in the regulation 
of DNA repair process (Figure 5). In particular, our results 
show that rpL3 has a strong effect in inhibiting the precise 
NHEJ known as classical end joing (Figure 5c).
Next, we verified whether rpL3’s effect on DNA 
repair processes occurred through p21 involvement. 
Although we observed an increase of rpL3 after treatment 
with either 5-FU or L-OHP, a different behavior of 
p21 was observed. In fact, 5-FU caused a decrease of 
p21 protein level whereas L-OHP was able to induce 
a marked increase of it (Figures 7c and 7d). Data from 
ChIP experiments and reporter luciferase assays showed 
that rpL3 affected p21 expression at transcriptional level 
acting as transcriptional activator or repressor in response 
to L-OHP or 5-FU, respectively (Figures 6 and 7). Our 
previous experiments demonstrated the existence of 
rpL3-NPM complex involved in the trans-activation of 
p21 promoter [21]. Since it is known that L-OHP is able 
to promote the nucleoplasmic translocation of NPM [4] 
we hypothesize that after L-OHP-induced nucleolar 
disruption, NPM is released from nucleolus and could 
be recruited by ribosome-free rpL3 to form rpL3-NPM 
complex active in p21 promoter induction. In contrast, 
5-FU does not induce the translocation of NPM into the 
nucleoplasm indicating that different protein factors could 
take part in rpL3-mediated regulation of p21 induced by 
this drug.
Nowadays the role of p21 in DNA repair has been 
poorly characterized [37–39]. Our results indicate that 
in p21-depleted cells, treated with 5-FU or L-OHP, rpL3 
silencing did not cause a reduction of DNA damage 
indicating that p21 was essential for rpL3 role to DNA 
repair (Figure 8). Of interest, the ectopic expression of 
rpL3 in untreated and drug-treated p21-depleted cells was 
associated to an increment of DNA damage suggesting 
that rpL3 inhibited DNA repair also independently from 
p21 (Figure 8).
To our knowledge a relationship between r-proteins 
and inhibition of DNA repair was not described. It 
is plausible that upon drug-induced ribosomal stress 
ribosome-free rpL3 could inhibit DNA repair directly or 
alternatively indirectly by repressing DNA repair proteins 
as p21. The identification of DNA repair proteins involved 
as well as rpL3-associated factors could clarify the role of 
free rpL3 in DNA repair.
The observation that in the absence of 
chemotherapeutic treatments, rpL3 did not affect p21 
promoter transactivation, cell cycle phases, DNA 
damage content and apoptosis strongly indicate that the 
extraribosomal function of rpL3 to control cell cycle 
and/or apoptosis through p21 regulation represents a 
pathway that is specifically activated upon drug-induced 
nucleolar stress.
Since reported data demonstrate that intracellular 
level of rpL3 can deeply influence cell response to drug 
treatments, the knowledge of rpL3 status in p53 null 
cancers may have a significant value in terms of the 
efficacy of chemotherapy based on 5-FU and L-OHP.
Figure 8: Role of p21 in the rpL3-mediated control of DNA repair. p21ΔCalu-6 cells transiently transfected with siRNA specific 
for rpL3 or scrambled siRNA (Scr) or pHA -rpL3, untreated and treated with 100 μM 5-FU or 10 μM L-OHP for 24 h were immunostained 
with an anti-γ-H2AX monoclonal antibody followed by secondary FITC-conjugate antibodies and analyzed by flow cytometry.
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In the light of these findings we hypothesize a 
working model by which the cell response to ribosomal 
stress caused by 5-FU and L-OHP is strongly influenced 
by the status of rpL3.
We predict that in physiological conditions, rpL3 
primarily resides in the ribosome and the intracellular 
amount of ribosome-free rpL3 is functional to tightly 
regulate its own expression [40]. Under specific ribosomal 
stress (i.e. 5-FU or L-OHP treatments), rpL3 could 
be protected from degradation, as occurred for some 
r-proteins [24], and accumulates outside the ribosome. 
The increased ribosome-free rpL3 could translocate from 
nucleolus to the nucleus where it might directly affect 
HR and NHEJ or alternatively indirectly by modulating 
p21 expression levels leading to an increase of DNA 
damage and, consequently, cell cycle arrest and apoptosis 
(Figure 9).
The cytotoxic effects of 5-FU and L-OHP including 
DNA damage, changes in cell cycle and apoptosis, 
failed to occur after the loss of rpL3 leading to cancer 
progression (Figure 9).
In conclusion, our results add new insights to the 
understanding of molecular mechanisms of 5-FU and 
L-OHP in p53 null tumors. In particular, we demonstrate 
that human rpL3 acts as stress sensing molecule essential 
to cell response to 5-FU and L-OHP chemotherapy in 
cancer lacking active p53.
MATERIALS AND METHODS
Cell cultures, transfections and drug treatments
Human cell lines Calu-6 [40], p21ΔCalu-6 [21], 
HCT 116 p53-/- and HeLa/DR-GFP were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) with 
glutamax (Invitrogen, Carlsbad, California) supplemented 
with 10% fetal bovine serum (FBS), 2 mM L-glutamine 
and penicillin-streptomycin 50 U/ml. Calu-6 and 
p21ΔCalu-6 cell medium was also supplemented with 
0.1 mM non-essential amino acids (Euroclone, West 
York, UK).
siRNA and plasmid transfections were performed in 
cells as previously described [20, 21].
The siRNA targeting rpL3 was purchased from 
Santa Cruz Biotechnology (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA, sc-76400).
Drug treatments were performed after siRNA or 
DNA transfection by adding to cells 100 μM of the 5-FU, 
10 μM of the L-OHP or 5 nM of ActD (Sigma-Aldrich, 
St. Louis, MO, USA) for 24 h. To block DNA-PK cells 
were treated with 10 μM of NU7026.
Ribosome isolation
Calu-6 or HCT 116 p53-/- cells were pelleted 
and resuspended in lysis buffer (10 mM NaCl, 
10 mM MgCl2, 10 mM Tris–HCl (pH 7.5), 0.5% 
NP-40, aprotinin 1 mg/ml, leupeptin 1 mg/ml, pepstatin A 
1 mg/ml, phenylmethylsulfonyl fluoride 100 mg/ml). 
After incubation in ice for 10 min, the extract was 
centrifuged for 1 min in a microcentrifuge at a maximum 
speed at 4°C and the supernatant (total extract) was 
frozen in liquid nitrogen. To isolate ribosomes and 
ribosomal subunits, the total extracts were spun at 
100 000 g for 2 h on 15% sucrose cushion. After 
centrifugation, the pellet (which includes polysomes and 
ribosomal subunits) was resuspended in Loading Buffer 
(63 mM Tris–HCl pH 6.8, 5% glycerol, 1% SDS, 2.5% 
bromophenol-blue) for western blot analysis, whereas the 
supernatant was precipitated with 10% trichloroacetic 
acid and resuspended in Loading Buffer for western blot 
analysis.
Figure 9: Schematic representation of proposed model. In the presence of rpL3 (rpL3 On), drug induced ribosomal stress caused 
an induction of rpL3 total intracellular levels and the accumulation of rpL3 as ribosome-free form. Free rpL3, directly and/or through 
alteration of p21 expression, inhibits HR and NHEJ processes leading to an increase of DNA damage and, in turn, to cell cycle arrest and 
apoptosis. In the absence of rpL3 (rpL3 Off), drug induced ribosomal stress did not associate to cell death. In this condition, no alteration 
of p21 level, HR and NHEJ were observed, cells survive and proliferate.
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Western blotting
Western blotting analysis was performed as 
previously reported [41]. The membranes were challenged 
with anti-rpL3, anti-rpL7a (Primm, Milan, Italy), anti-
rpS19 (Sigma-Aldrich), anti-p21 (Sigma-Aldrich), and 
anti-α-tubulin (Santa Cruz Biotechnology). Proteins were 
visualized with enhanced chemiluminescence detection 
reagent according to the manufacturer’s instructions 
(Pierce, Rockford, Illinois).
Chromatin immunoprecipitation
Chromatin immunoprecipitation assay was performed 
as previously reported [21].
Dual luciferase assay
Luciferase assays were performed with the Dual-Glo 
Luciferase assay system (Promega, Madison, Wisconsin, 
USA) following manufacturer’s instructions. Samples 
were read with Turner Luminometer and expressed as 
relative luciferase, i.e., RT/RC, where RT and RC are 
(Firefly luciferase)/(Renilla luciferase).
BrdU incorporation
For BrdU incorporation, Calu-6 cells or HCT 116 
p53-/- cells were labeled for 40 min with 20 μM BrdU 
(Sigma-Aldrich), harvested and fixed in 70% ethanol. 
Subsequently, cells were incubated with 20 μl of anti-
BrdU-FITC antibody (BD Biosciences, Italy) for 45 min 
in dark at room temperature. Cells were then washed 
twice with PBS 1 × and Tween 0.1%, centrifuged and 
resuspended in 1 ml of PBS containing 10 μg/ml of 
RNase and 5 μg/ml of propidium iodide (Sigma-Aldrich). 
Samples were analyzed by a CyAn ADP Flow Cytometer 
(DAKOCytomation) and quantified using Summit 
Software.
Mitochondrial membrane 
potential measurement
To quantify changes in mitochondrial membrane 
potential, Calu-6 cells or HCT 116 p53-/- cells were 
labeled with 50 nM of the mitochondrial membrane 
potential–sensitive fluorescent dye TMRE (Invitrogen), 
for 30 min at 37°C, analyzed by a CyAn ADP Flow 
Cytometer (DAKOCytomation) and quantified using 
Summit Software.
Flow cytometry for g-H2AX
To detect γ-H2AX, cells were fixed with 70% ethanol 
in PBS and routinely kept at -20°C overnight. Cells were 
washed with PBS and permeabilized with PBS, 4% fetal 
bovine serum, and 0.1% Triton X-100 for 10 min on ice. 
Cells were incubated with anti-γ-H2AX monoclonal 
antibody (JBW301 from Upstate Biotechnology), in a 
1:200 dilution in PBS, 4% fetal bovine serum, for 2 h. Cells 
were washed twice with PBS-T (PBS, Tween-20 0.1%) and 
incubated with 1:200 dilution of fluorescein-tagged goat 
anti-mouse secondary antibody (Santa Cruz Biotechnology).
After washes with PBS-T, cells were resuspended 
in PBS and were analyzed using a CyAn ADP Flow 
Cytometer (DAKOCytomation) and Summit Software.
Clonogenic assays
For clonogenic assay, Calu-6 cells cells were plated 
in triplicate at 4 × 103 in 6-well multidishes. After 5 to 
7 days, colonies were stained with 1% methylene blue in 
50% ethanol.
In vivo recombination assay system and analysis 
of homologous recombination frequency
HeLa/DR-GFP cells carrying a single integrated 
copy of GFP recombination reporter construct were kindly 
provided by Prof. E. Avvedimento. This reporter construct 
contains two GFP genes: one nonfunctional GFP gene 
mutated to contain a I-SceI cleavage site and an additional, 
truncated GFP gene that can correct the SceI site mutation. 
The I-SceI restriction endonuclease is used to introduce 
a DSB in the reporter gene. Chromosomal repair of the 
reporter gene by homologous recombination leads to GFP 
expression, which is analyzed by flow cytometry.
To examine the effect of rpL3 on DSB-induced 
homologous recombination, HeLa cells were transiently 
transfected with the I-SceI expression vector pCAGGS-
ISceI, in the presence or in the absence of siRNA for rpL3 
or scrambled siRNA. 48 h later, the percentage of GFP-
positive cells was determined by flow cytometry using 
a CyAn ADP Flow Cytometer (Beckman Coulter, Inc., 
Milano, Italy) and Summit Software.
In vivo end-joining assay
Plasmid pGL3 basic (Promega) was linearized 
with HindIII (recognition site between the promoter and 
the luciferase cDNA) or NarI (cleaves within the coding 
region of the luciferase cDNA). Cells were transiently 
cotransfected with circular, linearized plasmid and pRL-
SV40 Renilla luciferase plasmid, in the presence or in the 
absence of rpL3 siRNA or scrambled siRNA. After 48 h, 
cells were lysed in passive lysis buffer and analyzed by 
the dual luciferase assay (Promega). Repair efficiency 
was calculated from the luciferase activities of linearized 
reporter constructs compared with that of the intact plasmid.
Statistical analysis
Error bars represent mean ±s.d. from n = 3 biological 
replicates. *P < 0.05 was considered significant, **P < 0.01 
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was considered highly significant; Student t-test is used 
throughout.
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